Cartalax is a synthetic short tripeptide (Ala-Glu-Asp) studied primarily for its theoretical role in supporting cartilage, connective tissue, and cellular aging processes. However, it is not an approved medication for treating arthritis or joint injuries in humans.
Proposed Research Benefits
Cartilage and Joint Support: Laboratory models suggest it may influence chondrocyte gene expression and help maintain the extracellular matrix framework in joints.
Cellular Aging Modulation: Preclinical studies indicate a potential reduction in senescence markers (such as p16, p21, and p53) and an upregulation of longevity-associated sirtuins like SIRT6.
Tissue Resilience: Theories propose it might assist in supporting collagen synthesis pathways and recovery from mechanical wear and tear on connective tissues
Molecular Formula: C₁₂H₁₉N₃O₈
Molecular Weight:29 g/mol
Purity: ≥99%
Sequence: Ala-Glu-Asp
Purity: 99%

